Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Tudor Fulga

Visiting Professor of Genome Biology

I am now part of Vertex Pharmaceuticals as Vice President/Head of Gene Editing and Discovery Biology, but I remain associated with the MRC WIMM until October 2021 in the first instance, continuing with my existing collaborations and mentoring my existing graduate students. 

My group is focused on creating synthetic systems capable of rewiring or enhancing naturally-evolved cellular behaviours, and applying the underlying concepts to advance the scope of cell engineering approaches for basic research and therapeutic applications. This scientific program is inspired by advances in miRNA biology, synthetic biology and genome engineering, and supported by an interdisciplinary research infrastructure and key strategic collaborations.

I obtained my PhD from the European Molecular Biology Laboratory (EMBL) in Heidelberg, and subsequently received training at Harvard Medical School, first as a postdoctoral fellow and later as an Instructor in Cell Biology. As a graduate student, I initially studied the process of protein translocation across the ER with Irmgard Sinning, and later the cellular events controlling invasive cell migration with Pernille Rorth. I later joined the laboratory of Mel Feany at Harvard Medical School as a postdoctoral fellow, where I investigated the molecular mechanisms underlying neurodegeneration in Alzheimer’s disease. Subsequently, I was appointed Instructor in Cell Biology at Harvard Medical School and together with my advisor David Van Vactor I pioneered a highly versatile in vivo transgenic technology for conditional knockdown of miRNAs. In 2011/2012, I joined the Weatherall Institute of Molecular Medicine (WIMM) in Oxford as a Group Leader and MRC senior research fellow. In 2014 I was appointed Associate Professor of Genome Biology at Radcliffe Department of Medicine, University of Oxford.

Key publications

Recent publications

More publications